Is Jardiance (empagliflozin) appropriate for patients with impaired renal function (eGFR < 60 mL/min/1.73 m²)?

Jardiance Use in Low Kidney Function

Yes, Jardiance (empagliflozin) is appropriate and recommended for patients with impaired renal function down to an eGFR of 20 mL/min/1.73 m², particularly for cardiovascular and kidney protection, though glucose-lowering efficacy diminishes as kidney function declines. 1

Current Guideline Recommendations

The most recent consensus guidelines from ADA/KDIGO (2022) establish clear thresholds:

• Initiate empagliflozin in patients with eGFR ≥20 mL/min/1.73 m² for those with type 2 diabetes and chronic kidney disease 1
• Once started, continue empagliflozin even if eGFR falls below 20 mL/min/1.73 m² until dialysis is initiated 1
• The 2024 BMJ guideline for SGLT2 inhibitors in CKD (with or without diabetes) provides strong recommendations for moderate and very high-risk patients, weak recommendations for low and high-risk patients 2

This represents a significant evolution from older recommendations that restricted use at eGFR <30 or <45 mL/min/1.73 m².

Dosing by Kidney Function

For eGFR 30-44 mL/min/1.73 m² (Stage 3b CKD):

• Use empagliflozin 10 mg daily 1

For eGFR 15-29 mL/min/1.73 m² (Stage 4 CKD):

• FDA labeling states "use not recommended with eGFR <45 mL/min/1.73 m²" 3
• However, consensus guidelines supersede this: May continue 10 mg daily if already initiated, or initiate at 10 mg daily for cardiovascular/kidney benefit 1
• Note: Initiation not recommended with eGFR <30 mL/min/1.73 m² for glycemic control alone, but IS recommended for heart failure or kidney protection 1

For eGFR <20 mL/min/1.73 m²:

• Initiation not recommended due to insufficient data 3
• May continue if already on therapy and tolerating well 1

Contraindicated on dialysis 3

Key Clinical Context

Why Use Despite Reduced Glucose-Lowering Effect?

The glucose-lowering benefit decreases as eGFR declines, but cardiovascular and kidney protective benefits are preserved 1. The EMPA-KIDNEY trial (2023) demonstrated:

• 28% reduction in kidney disease progression or cardiovascular death (HR 0.72) across eGFR ranges down to 20 mL/min/1.73 m² 4
• Benefits consistent with or without diabetes 4
• EMPEROR trials showed efficacy in heart failure patients with eGFR ≥20 mL/min/1.73 m² 5

Expected Initial eGFR Decline

Empagliflozin causes a reversible initial decline in eGFR that does not require discontinuation 1. This hemodynamic effect is actually associated with long-term kidney protection. Do not stop the medication for this expected finding.

Safety Monitoring Requirements

Volume Depletion Risk:

• Higher risk in patients ≥75 years (4.4% vs 2.1% placebo) 3
• Consider proactive diuretic dose reduction in high-risk patients 1
• Hold during acute illness 1

Urinary Tract Infections:

• Increased risk in elderly (15.1-15.7% vs 10.5% placebo in those ≥75 years) 3

Genital Mycotic Infections:

• Occurs in ~6% vs 1% placebo 1
• Counsel on genital hygiene 1

Euglycemic Diabetic Ketoacidosis:

• Maintain at least low-dose insulin in insulin-requiring patients 1
• Institute sick day protocol (hold during illness) 1
• Monitor ketones if symptoms develop 1

Hypoglycemia:

• Adjust background insulin or sulfonylureas as needed 1

Common Pitfalls to Avoid

1. Don't discontinue for initial eGFR dip - This is expected and protective long-term
2. Don't withhold based on outdated FDA labeling - Guidelines now support use down to eGFR 20 mL/min/1.73 m²
3. Don't focus solely on glucose control - The primary benefit at low eGFR is cardiovascular and kidney protection
4. Don't forget sick day rules - Hold during acute illness, dehydration, or surgery

Specific Patient Populations Not Addressed

The 2024 BMJ guideline notes recommendations may not apply to 2:

• Kidney transplant recipients
• Polycystic kidney disease (though emerging case reports suggest potential benefit 6)
• Rare kidney diseases
• Patients on dialysis (contraindicated)